Clinical trials: Stage III Skin Cancer
Recurrent Melanoma, Stage III Melanoma
Tanespimycin in Treating Patients With Stage III-IV Melanoma
This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00087386
- Testing
- tanespimycin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00085488
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only.
- Trial name
- HOBOE (NCT00412022)
- Testing
- tamoxifen, triptorelin, letrozole
- Where
- 20 sites in Italy
- Volunteers
- 1,294 people
- Sponsor
- National Cancer Institute, Naples
Intraocular Melanoma, Melanoma (Skin)
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and lomustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072345
- Testing
- lomustine, temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Stage II, Breast Cancer Stage III
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated with either conventional…
- Trial name
- NCT03270072
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, TNBC
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve…
- Trial name
- NCT07021261
- Testing
- Utidelone plus capecitabine, Capecitabine
- Volunteers
- 440 people
- Sponsor
- Fudan University
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD.…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
- Trial name
- NCT04537156
- Testing
- Nonavalent HPV vaccine, Bivalent HPV vaccine
- Where
- 2 sites in China
- Volunteers
- 9,327 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Breast Cancer, Recurrent Breast Cancer
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain
RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast…
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01013337
- Testing
- acupuncture therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor.
- Trial name
- NCT00796445
- Testing
- GSK 2132231A
- Where
- 257 sites in United States, Argentina and 30 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms, Fever
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration of thrombocytopenia and the time to recovery of…
- Conditions
- Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia
- Trial name
- NCT00001338
- Testing
- FLAC chemotherapy with GM-CSF
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This randomized phase II trial studies how well fulvestrant works with or without bortezomib in treating patients with estrogen receptor positive breast cancer that has spread to other places in the body and cannot be removed by…
- Conditions
- Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01142401
- Testing
- Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 21 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-negative Breast Cancer, Male Breast Cancer
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
This phase II trial is studying saracatinib to see how well it works in treating patients with metastatic or locally advanced breast cancer that cannot be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00559507
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma
- Trial name
- NCT05741164
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
This randomized phase II trial studies how well electroacupuncture therapy works in reducing chronic pain in patients following surgery for stage I-III breast cancer.
- Conditions
- Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT02754752
- Testing
- Electroacupuncture Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Stage III or IV, No Prior Chemotherapy
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
Investigation of the metabolic activity of sorafenib and sorafenib plus dacarbazine on melanoma metastasis in patients with melanoma stage III or IV on the basis of PET/CT, LDH and S-100 evaluation.
- Trial name
- NCT00794235
- Testing
- Sorafenib (Nexavar), Dacarbazine (DTIC)
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
TC Avastin. ICORG 08-10, V6
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00911716
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- 8 sites in Denmark, Ireland
- Volunteers
- 106 people
- Sponsor
- Cancer Trials Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.